文献速递眼底病与葡萄膜炎

抗HtrA1抗体片段FHTR2163治疗地图样萎缩的1期研究

Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2021-06-29

这是一项1期开放标签、单次递增剂量与多次给药扩展研究,纳入≥50岁、继发于AMD的地图样萎缩且BCVA在Snellen 20/125至20/400之间的成人患者。第一阶段单次玻璃体腔注射FHTR2163 1至20 mg(5个剂量组,每组3例,共15例),第二阶段评估最大测试剂量20 mg每4周一次共3次(13例)。结果显示无剂量限制性毒性或眼部严重不良事件,最常报告的研究眼不良事件为结膜出血(7例)、结膜充血(4例)和眼痛(2例),无不良事件被评估为药物相关,房水中裂解DKK3水平显示持续药效学效应。

要点

  • FHTR2163在1至20 mg单次及20 mg多次玻璃体腔注射中耐受良好,无剂量限制性毒性或眼部严重不良事件。
  • 研究眼最常见不良事件为结膜出血(7例)、结膜充血(4例)和眼痛(2例),均未被评估为药物相关。
  • 房水中裂解DKK3水平显示抗HtrA1的持续药效学效应,20 mg为最大测试剂量。

核心结论

  • FHTR2163是一种靶向HtrA1的新型Fab,玻璃体腔注射耐受良好,无剂量限制性毒性或显著眼部不良事件。
  • 在最大测试剂量20 mg下注射3次后,分子显示出持续的药效学效应。

研究设计与样本

  • 1期、开放标签、单次递增剂量与多次给药扩展研究。
  • 纳入≥50岁、继发于AMD的地图样萎缩且最佳矫正视力在Snellen 20/125至20/400之间的成人患者。
  • 第一阶段:单次玻璃体腔注射FHTR2163,5个剂量递增组从1至20 mg,每组3例,共15例。
  • 第二阶段:评估最大测试剂量20 mg,每4周一次共3次,共13例。

主要发现

  • 未报告剂量限制性毒性或眼部严重不良事件。
  • 研究眼最常报告的不良事件为结膜出血(7例)、结膜充血(4例)和眼痛(2例)。
  • 无眼部或非眼部不良事件被评估为药物相关。
  • 眼部检查无临床显著变化。
  • 通过房水中裂解DKK3水平测定,观察到抗HtrA1的持续药效学效应。

临床怎么用

  • 该1期研究支持FHTR2163在继发于AMD的地图样萎缩患者中进一步开展临床研究。
  • 玻璃体腔注射FHTR2163 20 mg每4周一次共3次后观察到持续药效学效应。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: FHTR2163 is a novel antigen-binding fragment (Fab) directed against high-temperature requirement protein A1 (HtrA1). HTRA1 inhibition may preserve retinal integrity and slow disease progression in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This study examined the safety, pharmacokinetics, immunogenicity, and changes in the HTRA1-specific substrate Dickkop-related protein 3 (DKK3) in patients with GA who received FHTR2163. DESIGN: Phase I, open-label, single ascending dose escalation and multiple-dose expansion study. METHODS: Adults aged ≥ 50 years with GA secondary to AMD with best corrected visual acuity ranging between Snellen 20/125 and 20/400 were enrolled. In the first stage, a single intravitreal injection of FHTR2163 was given in 5 dose-escalation cohorts ranging from 1 to 20 mg (n = 3 patients/cohort; n = 15 total patients). The second stage evaluated the maximum tested dose of 20 mg administered every 4 weeks for 3 doses (n = 13 patients). RESULTS: No dose limiting toxicities or ocular serious AEs were reported. The most frequently reported AEs in the study eye were conjunctival hemorrhage (n = 7), conjunctival hyperemia (n = 4), and eye pain (n = 2). No non-ocular or ocular AEs were assessed as drug related. There were no clinically significant changes in ocular exams. A sustained pharmacodynamic effect of anti-HtrA1 was observed in the aqueous humor, as measured by levels of cleaved DKK3. CONCLUSIONS: FHTR2163, a novel Fab directed against HtrA1, was well tolerated with no DLTs or significant ocular AEs. The molecule when injected intravitreally for 3 doses showed a sustained pharmacodynamic effect at the maximum tested dose of 20 mg.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Khanani AM, Hershberger VS, Pieramici DJ, et al. Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration. Am J Ophthalmol. 2021. PMID: 34214452. doi:10.1016/j.ajo.2021.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。